CASI Pharmaceuticals, Inc. (NASDAQ:CASI – Get Rating) – Equities research analysts at Oppenheimer lowered their FY2025 earnings per share estimates for CASI Pharmaceuticals in a research note issued to investors on Thursday, May 12th. Oppenheimer analyst L. Gershell now anticipates that the biotechnology company will earn $0.61 per share for the year, down from their prior forecast of $0.72.
CASI has been the subject of several other reports. Zacks Investment Research upgraded CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday. HC Wainwright decreased their price target on CASI Pharmaceuticals from $4.00 to $3.00 in a research note on Friday. Finally, StockNews.com assumed coverage on CASI Pharmaceuticals in a research note on Saturday. They issued a “hold” rating on the stock.
CASI Pharmaceuticals (NASDAQ:CASI – Get Rating) last posted its earnings results on Thursday, May 12th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.03. CASI Pharmaceuticals had a negative return on equity of 35.39% and a negative net margin of 93.65%. During the same period last year, the firm earned ($0.11) EPS.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Marshall Wace LLP acquired a new position in CASI Pharmaceuticals during the 1st quarter worth about $44,000. UBS Group AG lifted its stake in CASI Pharmaceuticals by 493.1% during the 3rd quarter. UBS Group AG now owns 26,715 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 22,211 shares in the last quarter. Citadel Advisors LLC acquired a new position in CASI Pharmaceuticals during the 3rd quarter worth about $35,000. Morgan Stanley lifted its stake in CASI Pharmaceuticals by 781.2% during the 2nd quarter. Morgan Stanley now owns 43,285 shares of the biotechnology company’s stock worth $68,000 after acquiring an additional 38,373 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in CASI Pharmaceuticals during the 3rd quarter worth about $72,000. 39.51% of the stock is currently owned by hedge funds and other institutional investors.
About CASI Pharmaceuticals (Get Rating)
CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.
- Get a free copy of the StockNews.com research report on CASI Pharmaceuticals (CASI)
- Volatile Times Are When AbbVie Shines the Brightest
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.